Advertisement
MLTX vs ZYME
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLTX is a StrongBuy and ZYME is a StrongBuy.
MLTX in +19.57% Uptrend, growing for three consecutive days on October 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Indicator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 68 cases where MLTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on MLTX as a result. In 83 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
MLTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MLTX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.347) is normal, around the industry mean (3.037). P/E Ratio (-3.076) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for ZYME turns positive, indicating new upward trend
ZYME saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 75 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ZYME just turned positive on October 20, 2026. Looking at past instances where ZYME's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
ZYME moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYME advanced for three days, in 252 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ZYME crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
ZYME broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZYME entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.328) is normal, around the industry mean (3.037). P/E Ratio (-14.045) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MLTX | ZYME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 96 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 40 | |
P/E GROWTH RATING 1..100 | 13 | 65 | |
SEASONALITY SCORE 1..100 | 50 | 2 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MLTX's Valuation (38) in the null industry is somewhat better than the same rating for ZYME (82) in the Pharmaceuticals Major industry. This means that MLTX’s stock grew somewhat faster than ZYME’s over the last 12 months.
MLTX's Profit vs Risk Rating (96) in the null industry is in the same range as ZYME (100) in the Pharmaceuticals Major industry. This means that MLTX’s stock grew similarly to ZYME’s over the last 12 months.
MLTX's SMR Rating (98) in the null industry is in the same range as ZYME (98) in the Pharmaceuticals Major industry. This means that MLTX’s stock grew similarly to ZYME’s over the last 12 months.
ZYME's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as MLTX (63) in the null industry. This means that ZYME’s stock grew similarly to MLTX’s over the last 12 months.
MLTX's P/E Growth Rating (13) in the null industry is somewhat better than the same rating for ZYME (65) in the Pharmaceuticals Major industry. This means that MLTX’s stock grew somewhat faster than ZYME’s over the last 12 months.
| MLTX | ZYME | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | N/A |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 84% |
| Advances ODDS (%) | 6 days ago 84% | 6 days ago 85% |
| Declines ODDS (%) | 2 days ago 80% | 14 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MLTX’s FA Score shows that 1 FA rating(s) are green while ZYME’s FA Score has 0 green FA rating(s).
- MLTX’s FA Score: 1 green, 4 red.
- ZYME’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MLTX’s TA Score shows that 5 TA indicator(s) are bullish while ZYME’s TA Score has 4 bullish TA indicator(s).
- MLTX’s TA Score: 5 bullish, 3 bearish.
- ZYME’s TA Score: 4 bullish, 5 bearish.
Price Growth
MLTX (@Biotechnology) experienced а +21.13% price change this week, while ZYME (@Biotechnology) price change was +11.08% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.84%. For the same industry, the average monthly price growth was -11.13%, and the average quarterly price growth was -13.98%.
Reported Earning Dates
MLTX is expected to report earnings on Nov 04, 2026.
ZYME is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (+3.84% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement